Cover Image

Prolonged survival after intraperitoneal interleukin-2 immunotherapy for recurrent ovarian cancer

Saved in:

Bibliographic Details
Main Authors:	David R. Minor (Author), Samantha P. Moores (Author), John K. Chan (Author)
Format:	Book
Published:	Elsevier, 2017-11-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Long-term durable responses after pembrolizumab immunotherapy for recurrent, resistant endometrial cancer
by: John K. Chan, et al.
Published: (2020)

Long-term survival after intraperitoneal chemotherapy with paclitaxel-cisplatin for recurrent primary peritoneal cancer resistant to multiple lines of intravenous chemotherapy
by: Hyejeong Hue, et al.
Published: (2019)

Intraperitoneal chemotherapy in the management of ovarian cancer: focus on carboplatin
by: Maurie Markman
Published: (2009)

Hyperthermic intraperitoneal chemotherapy as consolidation treatment of advanced stage ovarian cancer
by: Jieun Ko, et al.
Published: (2021)

Role of hyperthermic intraperitoneal chemotherapy in combination with an intraperitoneal port system in the treatment of patients with advanced ovarian cancer
by: V. V. Saevets, et al.
Published: (2022)

Intraperitoneal splenosis mimics peritoneal carcinomatosis of leiomyosarcoma and ovarian cancer
by: Yu-Chien Lin, et al.
Published: (2020)

Specific features of current intraperitoneal therapy in patients with ovarian cancer
by: A. G. Kedrova, et al.
Published: (2016)

Intraperitoneal biotherapy of malignant peritoneal effusions in ovarian cancer patients
by: К. S. Titov, et al.
Published: (2014)

Profound sensorineural hearing loss after one cycle of intraperitoneal cisplatin in treatment of advanced ovarian cancer
by: Megan E. McDonald, et al.
Published: (2017)

Research progress of interleukin-15 in cancer immunotherapy
by: Menghan Cai, et al.
Published: (2023)

The addition of sodium thiosulphate to hyperthermic intraperitoneal chemotherapy with cisplatin in ovarian cancer
by: Kate Glennon, et al.
Published: (2021)

Assessment of travel distance for hyperthermic intraperitoneal chemotherapy in women with ovarian cancer
by: Laura M. Chambers, et al.
Published: (2022)

Recurrent pleural effusion as a rare manifestation after prolonged PD1 inhibitor (camrelizumab)-based immunotherapy: A case report
by: Xiao-Hong Xie, et al.
Published: (2023)

Comment on: hyperthermic intraperitoneal chemotherapy as consolidation treatment of advanced stage ovarian cancer
by: Shalini Venkatappa, et al.
Published: (2022)

Nanotechnology for boosting ovarian cancer immunotherapy
by: Prabhjot Kaur, et al.
Published: (2024)

Comprehensive bioinformatic analysis constructs a CXCL model for predicting survival and immunotherapy effectiveness in ovarian cancer
by: Shuang Li, et al.
Published: (2023)

Late Recurrence of Ovarian Cancer after 18 Years of Disease-Free Survival: A Case Report and Review of the Literature
by: Yoko Suzuki, et al.
Published: (2024)

PLGA Nanoparticles for the Intraperitoneal Administration of CBD in the Treatment of Ovarian Cancer: In Vitro and In Ovo Assessment
by: Ana I. Fraguas-Sánchez, et al.
Published: (2020)

Recurrent high grade serous endometrial cancer with brain metastases: Immunotherapy confers improved quality of life and survival
by: Kierany B. Shelvin, et al.
Published: (2024)

Recurrent ovarian cancer: prolongation of the platinum-free interval with the use of a weekly treatment regimen of hycamtin (topotecan)
by: E. G. Novikova, et al.
Published: (2014)

A case of severe encephalitis while on PD-1 immunotherapy for recurrent clear cell ovarian cancer
by: Morgan Burke, et al.
Published: (2018)

Initiation and elongation factor co-expression correlates with recurrence and survival in epithelial ovarian cancer
by: Monika Sobočan, et al.
Published: (2022)

Commment on the review entitled "A critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer" by Chiva LM and Gonzalez-Martin A.
by: Marcello Deraco, et al.
Published: (2016)

Elevated tumor mutational burden and prolonged clinical response to anti-PD-L1 antibody in platinum-resistant recurrent ovarian cancer
by: Christopher B. Morse, et al.
Published: (2017)

Toxicity of intraperitoneal chemotherapy and risk factors for severe toxicity in optimally debulked ovarian cancer patients
by: Yu-Jin Koo, et al.
Published: (2015)

EXPERIENCE WITH INTRAPERITONEAL CHEMOTHERAPY USING ASCITIC FLUID AS A SOLVENT OF CHEMICALS IN THE TREATMENT OF OVARIAN CANCER
by: Yu. S. Sidorenko, et al.
Published: (2014)

Calculating the dose of cisplatin that is actually utilized in hyperthermic intraperitoneal chemotherapy among ovarian cancer patients
by: Wu-yun Wang, et al.
Published: (2021)

mPEG-PDLLA Micelles Potentiate Docetaxel for Intraperitoneal Chemotherapy in Ovarian Cancer Peritoneal Metastasis
by: Yumei Zhang, et al.
Published: (2022)

Therapeutic Targeting of AXL Receptor Tyrosine Kinase Inhibits Tumor Growth and Intraperitoneal Metastasis in Ovarian Cancer Models
by: Pinar Kanlikilicer, et al.
Published: (2017)

The intratumoral microbiota biomarkers for predicting survival and efficacy of immunotherapy in patients with ovarian serous cystadenocarcinoma
by: Hao Qin, et al.
Published: (2024)

Prolonged survival in a patient with isolated skull recurrence of cervical carcinoma - Case report and review of the literature
by: Ariel Zilberlicht, et al.
Published: (2015)

Recurrent colon perforation after discontinuation of bevacizumab for ovarian cancer
by: Michiko Nonaka, et al.
Published: (2018)

Prolonged effect of allergen sublingual immunotherapy to grass pollen
by: Andrzej Bozek, et al.
Published: (2018)

Efficacy and safety of intraperitoneal bevacizumab combined with hyperthermic intraperitoneal chemotherapy in the treatment of patients with ovarian cancer and peritoneal effusion and the effect on serum lncRNA H19 and VEGF levels
by: Meiling Zhang, et al.
Published: (2023)

Immunotherapy for Recurrent and Metastatic Cervical Cancer: A Review
by: Yuke Wu, et al.
Published: (2024)

Successful surgical treatment of recurrent choriocarcinoma with laparoscopic resection of intraperitoneal pelvic tumor
by: Kuan-Gen Huang, et al.
Published: (2013)

Characterization of CPH:SA microparticle‐based delivery of interleukin‐1 alpha for cancer immunotherapy
by: M. M. Hasibuzzaman, et al.
Published: (2023)

Interval between secondary cytoreductive surgery and adjuvant chemotherapy is not associated with survivals in patients with recurrent ovarian cancer
by: Soo Young Jeong, et al.
Published: (2019)

Influence of lymphadenectomy on survival and recurrence in patients with early-stage epithelial ovarian cancer: a meta-analysis
by: Chenchen Yang, et al.
Published: (2023)

Recurrent ovarian torsion in an adolescent after oophoropexy
by: Erin K. Fee, et al.
Published: (2017)